ResearcherUniversity of UtahNo recent work listed

Mark R. Silvis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0717-1983; OpenAlex author ID A5030035753. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper

Papers 1

MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. Co-author DOI 10.1084/jem.20221524 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Kajsa E. Affolter · 1 shared paper, 2023 · strength 0.18
- Paper MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. DOI 10.1084/jem.20221524 ↗
Martin McMahon · 1 shared paper, 2023 · strength 0.18
- Paper MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. DOI 10.1084/jem.20221524 ↗
Conan Kinsey · 1 shared paper, 2023 · strength 0.18
- Paper MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. DOI 10.1084/jem.20221524 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.